|
|
 |
|
Viewing report
|
|
|
|
DPP IV Inhibitors - Global Strategic Business Report
Global Industry Analysts, Inc, Sep 2011, Pages: 363
This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin among others). The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017.
The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly And Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
|
|
|
|
